文献速递新药、器械与细胞基因治疗研发临床试验与 GCP基础与转化研究

单剂基因替代疗法治疗脊髓性肌萎缩症

Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy.
PubMed 文献 · N Engl J Med · 2017-01-01

本文报告15例SMA1患者接受单次静脉输注携带SMN cDNA的AAV9载体的研究,主要终点为安全性,次要终点为死亡或需永久通气时间;截至2017年8月7日,15例全部存活且无事件至20月龄,历史队列生存率为8%,高剂量队列CHOP INTEND评分较基线快速升高且运动里程碑达成优于历史队列。

要点

  • 15例SMA1患者接受单次静脉AAV9-SMN基因替代治疗,主要终点为安全性。
  • 截至2017年8月7日,15例全部存活且无事件至20月龄,历史队列生存率为8%。
  • 高剂量队列CHOP INTEND评分1个月增9.8分、3个月增15.4分,历史队列同期下降。

核心结论

  • SMA1患者单次静脉输注含SMN编码DNA的AAV载体后,生存期、运动里程碑达成及运动功能均优于历史队列。
  • 原文指出需进一步研究确认该基因疗法的安全性和有效性。

研究设计与样本

  • 15例SMA1患者接受单次静脉输注携带SMN cDNA的AAV9载体。
  • 3例接受低剂量6.7×10^13 vg/kg体重,12例接受高剂量2.0×10^14 vg/kg体重。
  • 主要终点为安全性,次要终点为至死亡或需永久通气辅助的时间。
  • 探索性分析比较两队列CHOP INTEND评分(0–64分,分值越高功能越好)及高剂量队列与自然病史研究(历史队列)的运动里程碑。

主要发现

  • 截至2017年8月7日数据截止,全部15例存活且无事件至20月龄,历史队列生存率为8%。
  • 高剂量队列CHOP INTEND评分自基线快速升高,1个月增加9.8分、3个月增加15.4分,历史队列同期该评分下降。
  • 高剂量队列12例中,11例可独坐、9例可翻身、11例可经口进食并可说话、2例可独立行走。
  • 4例出现血清转氨酶升高,经泼尼松龙治疗后减轻。

关键数值与推荐

  • 低剂量为6.7×10^13 vg/kg体重,高剂量为2.0×10^14 vg/kg体重。
  • CHOP INTEND评分范围0–64分,分值越高表示功能越好。
  • 高剂量队列CHOP INTEND评分1个月较基线增加9.8分、3个月增加15.4分。
  • 4例血清转氨酶升高,经泼尼松龙治疗后减轻。

临床怎么用

  • 原文报告SMA1患者单次静脉AAV9-SMN基因替代治疗后生存期、运动里程碑及运动功能优于历史队列。
  • 原文指出需进一步研究确认该基因疗法的安全性和有效性。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Spinal muscular atrophy type 1 (SMA1) is a progressive, monogenic motor neuron disease with an onset during infancy that results in failure to achieve motor milestones and in death or the need for mechanical ventilation by 2 years of age. We studied functional replacement of the mutated gene encoding survival motor neuron 1 (SMN1) in this disease. METHODS: Fifteen patients with SMA1 received a single dose of intravenous adeno-associated virus serotype 9 carrying SMN complementary DNA encoding the missing SMN protein. Three of the patients received a low dose (6.7×1013 vg per kilogram of body weight), and 12 received a high dose (2.0×1014 vg per kilogram). The primary outcome was safety. The secondary outcome was the time until death or the need for permanent ventilatory assistance. In exploratory analyses, we compared scores on the CHOP INTEND (Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders) scale of motor function (ranging from 0 to 64, with higher scores indicating better function) in the two cohorts and motor milestones in the high-dose cohort with scores in studies of the natural history of the disease (historical cohorts). RESULTS: As of the data cutoff on August 7, 2017, all 15 patients were alive and event-free at 20 months of age, as compared with a rate of survival of 8% in a historical cohort. In the high-dose cohort, a rapid increase from baseline in the score on the CHOP INTEND scale followed gene delivery, with an increase of 9.8 points at 1 month and 15.4 points at 3 months, as compared with a decline in this score in a historical cohort. Of the 12 patients who had received the high dose, 11 sat unassisted, 9 rolled over, 11 fed orally and could speak, and 2 walked independently. Elevated serum aminotransferase levels occurred in 4 patients and were attenuated by prednisolone. CONCLUSIONS: In patients with SMA1, a single intravenous infusion of adeno-associated viral vector containing DNA coding for SMN resulted in longer survival, superior achievement of motor milestones, and better motor function than in historical cohorts. Further studies are necessary to confirm the safety and efficacy of this gene therapy. (Funded by AveXis and others; ClinicalTrials.gov number, NCT02122952 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Mendell JR, Al-Zaidy S, Shell R, et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med. 2017. PMID: 29091557. doi:10.1056/NEJMoa1706198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。